S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
Log in

ASX:RGS - Regeneus Stock Price, Forecast & News

A$0.07
-0.01 (-12.50 %)
(As of 03/31/2020 04:00 PM ET)
Today's Range
A$0.07
Now: A$0.07
A$0.07
50-Day Range
A$0.05
MA: A$0.07
A$0.08
52-Week Range
A$0.05
Now: A$0.07
A$0.12
Volume196,745 shs
Average VolumeN/A
Market Capitalization$19.45 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Regeneus Ltd, a clinical-stage regenerative medicine company, engages in developing cell-based therapies for the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, and oncology and dermatology diseases. The company is developing its therapeutic products using its proprietary stem cell and immuno-oncology technology platforms. Its products under development for human health market include Progenza, a cell therapy that has completed Phase I clinical trial for the treatment of osteoarthritis and other musculoskeletal disorders; RGSH4K, a cancer vaccine, which is in Phase I clinical trial for the treatment of solid tumors; and Sygenus allogeneic cell secretion for use as a topical application for the treatment of acne and other inflammatory skin conditions, and wound healing. The company's animal health products comprise CryoShot, an allogeneic stem cell therapy for the treatment of canine and equine osteoarthritis, and other musculoskeletal disorders; and Kvax, an autologous cancer vaccine. Regeneus Ltd was founded in 2007 and is headquartered in Pymble, Australia.
Read More

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 9499 8010

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.45 million
Cash FlowA$0.00 per share
Book ValueA$0.00 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$19.45 million
Next Earnings DateN/A
OptionableOptionable

Receive RGS News and Ratings via Email

Sign-up to receive the latest news and ratings for RGS and its competitors with MarketBeat's FREE daily newsletter.


Regeneus (ASX:RGS) Frequently Asked Questions

How has Regeneus' stock been impacted by COVID-19 (Coronavirus)?

Regeneus' stock was trading at A$0.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RGS stock has increased by 4.5% and is now trading at A$0.07. View which stocks have been mosted impacted by Coronavirus.

Has Regeneus been receiving favorable news coverage?

Media stories about RGS stock have trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Regeneus earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View the latest news aboutRegeneus.

Who are some of Regeneus' key competitors?

Who are Regeneus' key executives?

Regeneus' management team includes the following people:
  • Mr. Leo Lee, CEO & Director (Age 49)
  • Prof. Graham Vesey, Chief Scientific Officer & Exec. Director (Age 54)
  • Mr. John Bird, Chief Financial & Operations Officer
  • Ms. Sandra McIntosh, HR Mang., Investor Relations Mang. & Company Sec.
  • Mr. Duncan Thomson, Head of the Veterinary Health Bus. Unit and VP of Licensing & Alliances

What is Regeneus' stock symbol?

Regeneus trades on the ASX under the ticker symbol "RGS."

What is Regeneus' stock price today?

One share of RGS stock can currently be purchased for approximately A$0.07.

How big of a company is Regeneus?

Regeneus has a market capitalization of $19.45 million and generates $1.45 million in revenue each year.  View additional information about Regeneus.

What is Regeneus' official website?

The official website for Regeneus is http://regeneus.com.au/.

How can I contact Regeneus?

The company can be reached via phone at 61 2 9499 8010.


MarketBeat Community Rating for Regeneus (ASX RGS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  8 (Vote Outperform)
Underperform Votes:  9 (Vote Underperform)
Total Votes:  17
MarketBeat's community ratings are surveys of what our community members think about Regeneus and other stocks. Vote "Outperform" if you believe RGS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel